-

EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent Biosolutions Inc. - EBS

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company’s shares between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Maryland.

What You May Do

If you purchased shares of Emergent and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-ebs/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 18, 2021.

About the Lawsuit

Emergent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 31, 2021, post-market, news media outlets reported that the Company’s employees at its Bayview facility had conflated or “mixed up” ingredients for the Johnson & Johnson and AstraZeneca COVID-19 vaccines, ruining up to 15 million doses of the J&J vaccine, and that this occurrence was not an isolated event but was part of a history of manufacturing issues at the Company’s plant.

On this news, shares of Emergent plummeted over 15% over the next two trading days, from a closing price of $92.91 per share on March 31, 2021, to close at $78.62 on April 5, 2021.

The case is Palm Tran, Inc. – Amalgamated Transit Union Local 1577 Pension Plan v. Emergent Biosolutions Inc. et al, 8:21cv955.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Industry:

Kahn Swick & Foti, LLC

NYSE:EBS
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Avenzo Therapeutics, Inc. Upon completion of the proposed transaction, pre-Transaction Rallybio equityholders are expected to own approximately 2.8% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, o...

Taylor Morrison Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taylor Morrison Home Corporation - TMHC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taylor Morrison Home Corporation (NYSE: TMHC) to Berkshire Hathaway Inc. (NYSE: BRK.A; BRK.B). Under the terms of the proposed transaction, shareholders of Taylor Morrison will receive $72.50 in cash for each share of Taylor Morrison that they own. KSF is seeking to determine whether this consi...

Select Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Select Medical Holdings Corporation - SEM

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Select Medical Holdings Corporation (NYSE: SEM) to a consortium led by Select Medical executives and directors. Under the terms of the proposed transaction, shareholders of Select Medical will receive $16.50 in cash for each share of Select Medical that they own. KSF is seeking to determine whet...
Back to Newsroom